APTX News and Press, Aptinyx Inc. From 02/03/22

Leading experts in neuroscience will provide guidance to support the advancement of Aptinyx’s novel NMDA receptor modulation platform and pipeline Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treat...

Catalyst-rich year with data readouts expected from three Phase 2 studies across chronic pain and cognitive impairment development programs Advancing PTSD development program with initiation of Phase 2b studies Strong balance sheet expected to fund Phase 2 readouts fro...

Event will review the company’s pipeline of clinical development programs, with a deep dive on NYX-2925 and chronic pain Featured presentation by Dr. Richard Rauck, board certified physician in pain medicine and anesthesiology at Carolinas Pain Institute and medical...

Aptinyx (NASDAQ:APTX) has initiated a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD). Shares up 2.9% premarket at $2.80. The company anticipates reporting data from the Phase 2b study in H2 2023. The NYX-783 Phase 2b PTSD pro...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stre...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will present at the 40 th Annual J.P. M...

A series of insider purchases have propelled microcap biotech Aptinyx (NASDAQ:APTX) higher. The latest to purchase company shares was Aptinyx (APTX) CEO, Norbert G. Riedel. In a transaction dated Dec. 06, Riedel has bought 100K shares, the company disclosed in a regulatory filing on Wedn...

Aptinyx (APTX +6.7%) shares have surged after Ashish Khanna, Chief Financial Officer (CFO) and Chief Business Officer (CBO), purchased 45,000 company shares, worth ~$100K. The shares were bought at $2.18 - $2.32 in a transaction dated Dec. 02, 2021. Form 4 A look at Aptinyx's ownership compos...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a fireside chat at the Piper Sandler 33 rd Annual Virtual ...

Kezar Life Sciences (NASDAQ:KZR) +46% on phase 2 data for lupus candidate Axon Enterprise (NASDAQ:AXON) +24% on Q3 results Cyclo Therapeutics (NASDAQ:CYTH) +19% on Q3 results. Comstock Holding Companies (NASDAQ:CHCI) +20% on Q3 results. Romeo Power (NYS...